One retrospective study of 27 patients with metastatic PIK3CA-mutated breast cancer treated with alpelisib showed no difference in response to alpelisib according to BMI (p = 0.966), although the study was limited by the small sample size [112]. The gene discussed is PIK3CA; the disease is breast carcinoma.